What is the long-term trend for Journey Medical Corporation's repayments of notes payable?

Over 2 years (2021 to 2023), Journey Medical Corporation's repayments of notes payable has grown at a -56.6% compound annual growth rate (CAGR), from $5.3M to $1M.

Journey Medical Corporation DERM Repayments Of Notes Payable

Repayments Of Notes Payable at other companies

Cumberland PharmaceuticalsCPIX

——

Other financials

Income statement

See full

Revenue$16.0M+21.5%

Gross profit$9.7M+16.7%

Operating income-$1.5M+55.1%

Net income-$2.2M+45.2%

EPS (diluted)-$0.08+55.6%

Balance sheet

See full

Cash & equivalents$27.2M+29.2%

Total debt$25.5M+1.2%

Total equity$30.8M+43.1%

Total assets$91.5M+7.7%

Cash flow

See full

Operating cash flow$2.9M+203%

CapEx$3.8M—

Free cash flow-$6.0M—

Valuation

See full

Market cap$194.94M+20.9%

Enterprise value$193.19M+16.2%

P/S3×+0.2×

Profitability

See full

Gross margin65.4%-1.0pp

Operating margin-9.8%—

Net margin-14.8%—

FCF margin-43%—

Returns & leverage

See full

Return on equity-36.6%—

Debt / equity0.8×-0.3×

Current ratio1.7×+0.4×

Where this comes from

Reported directly by Journey Medical Corporation in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfNotesPayable.

The official record: Journey Medical Corporation’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's repayments of notes payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Journey Medical Corporation's repayments of notes payable?: Journey Medical Corporation (DERM) reported repayments of notes payable of $625K in Q1 2025.
What is the long-term trend for Journey Medical Corporation's repayments of notes payable?: Over 2 years (2021 to 2023), Journey Medical Corporation's repayments of notes payable has grown at a -56.6% compound annual growth rate (CAGR), from $5.3M to $1M.